[HTML][HTML] A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
MJ Ramos, TJ Kendall, I Drozdov, JA Fallowfield - Annals of Hepatology, 2024 - Elsevier
Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by the presence
of liver steatosis together with at least one out of five cardiometabolic factors, is the most …
of liver steatosis together with at least one out of five cardiometabolic factors, is the most …
[HTML][HTML] Machine Learning Enables Single-Score Assessment of MASLD Presence and Severity
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of the global
population but is often underdiagnosed. To fill this diagnostic gap, we developed a digital …
population but is often underdiagnosed. To fill this diagnostic gap, we developed a digital …
[HTML][HTML] A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis
MS Sherman, PK Challa… - Hepatology …, 2024 - journals.lww.com
Background: Histopathology remains the gold standard for diagnosing and staging
metabolic dysfunction–associated steatotic liver disease (MASLD). The feasibility of studying …
metabolic dysfunction–associated steatotic liver disease (MASLD). The feasibility of studying …
[HTML][HTML] The gene expression signature of metabolic dysfunction-associated steatotic liver disease from a multiomics perspective
CJ Pirola, S Sookoian - Clinical and Molecular Hepatology, 2024 - ncbi.nlm.nih.gov
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe clinical
form, metabolic dysfunctionassociated steatohepatitis (MASH), are chronic liver diseases …
form, metabolic dysfunctionassociated steatohepatitis (MASH), are chronic liver diseases …
[HTML][HTML] Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
S Oh, YH Baek, S Jung, S Yoon, B Kang… - Clinical and …, 2024 - ncbi.nlm.nih.gov
Methods Biopsy-tissue and blood samples from patients with 134 MASLD, comprising 60
steatosis and 74 MASH patients were performed omics analysis. SVM learning algorithm …
steatosis and 74 MASH patients were performed omics analysis. SVM learning algorithm …
Liver-Quant: Feature-Based Image Analysis Toolkit for Automatic Quantification of Metabolic Dysfunction-Associated Steatotic Liver Disease
M Farzi, C McGenity, A Cratchley, L Leplat… - medRxiv, 2024 - medrxiv.org
Introduction: The histological assessment of liver biopsies by pathologists serves as the gold
standard for diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD) …
standard for diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD) …
[HTML][HTML] Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
J Trinks, MF Mascardi, A Gadano… - World Journal of …, 2024 - ncbi.nlm.nih.gov
Unmet needs exist in metabolic dysfunction-associated steatotic liver disease (MASLD) risk
stratification. Our ability to identify patients with MASLD with advanced fibrosis and at higher …
stratification. Our ability to identify patients with MASLD with advanced fibrosis and at higher …
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information
M McTeer, D Applegate, P Mesenbrink, V Ratziu… - Plos one, 2024 - journals.plos.org
Aims Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as
MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are …
MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are …
[HTML][HTML] Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records
Abstract Introduction and Objectives Despite the huge clinical burden of MASLD, validated
tools for early risk stratification are lacking, and heterogeneous disease expression and a …
tools for early risk stratification are lacking, and heterogeneous disease expression and a …
Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation
Metabolic dysfunction-associated steatotic liver disease (MASLD), liver with more than 5.5%
fat content, is a leading risk factor for chronic liver disease with an estimated worldwide …
fat content, is a leading risk factor for chronic liver disease with an estimated worldwide …